The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.
This article was originally published by Dermatology Times.
An open-label extension study (NCT01949311) has demonstrated acceptable safety of dupilumab (Dupixent) in treating adult patients with moderate to severe atopic dermatitis (AD) for up to 5 years, according to results presented in a poster session at the 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada.
The LIBERTY AD OLE trial involved a multicenter, phase 3 study that extended for up to 5 years. Adult patients with moderate to severe AD, who had previously participated in dupilumab clinical trials, received a weekly dose of 300 mg. Some patients transitioned to 300 mg every 2 weeks (q2w) to align with approved dosage.
Concomitant treatments, including topical corticosteroids (TCS) and topical calcineurin inhibitors, were allowed. The study lacked a control arm, so data from the LIBERTY AD CHRONOS trial provided comparative 52-week safety results for patients receiving dupilumab 300 mg qw plus TCS.
Adult patient with atopic dermatitis (AD)
Image credit: Monstar Studios - stock.adobe.com
The OLE trial included 2677 patients, with 60.2% being male and 72.3% identifying as White. The mean age of patients was 39.2 years, and the average duration of AD was 29.9 years. Baseline scores for Eczema Area and Severity Index, Investigator’s Global Assessment, and Peak Pruritus Numerical Rating Scale were 16.4, 2.7, and 5.0, respectively.
The safety profile of long-term dupilumab treatment for up to 5 years was found to be acceptable and consistent with previous findings from placebo-controlled studies. Exposure-adjusted incidence rates of treatment-emergent adverse events (TEAEs) did not increase over time and were lower than those reported in the 3- and 4-year analyses of the OLE trial and a previous 52-week placebo-controlled trial.
The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD and provide valuable insights for clinicians considering long-term treatment options for their patients. Continued monitoring and research in this area will further enhance understanding of dupilumab's safety profile.
Reference
Beck L, Bissonnette R, Deleuran M, et al. Safety of long-term dupilumab treatment in adults with moderate-to-severe results from a 5-year open-label extension trial. Poster presented at: 2023 Fall Clinical Dermatology Conference; October 19-22, 2023; Las Vegas, Nevada.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More